Pediatric liver transplantation is a fast-growing and challenging field. Healthcare providers must stay informed of advancements in the management of liver transplant candidates and recipients. The goal of this paper is to provide nurses who care for pediatric liver transplant candidates and recipients with a review of the basic medical management of these patients, from the preoperative evaluation to postoperative care.
Get full access to this article
View all access options for this article.
References
1.
StarzlTEMarhchioroTLVon KaullaK. Homotransplantation of the liver in humans. Surg Gynecol Obstet.1963;117:659–676.
Transplant Patient Data Source.United Network for Organ Sharing. Available at: http://207.239.150.13/tpd/. Accessed April 24, 2001.
4.
GhobrialRMFarmerDGAmersiFBusuttilRW. Advances in pediatric liver and intestinal transplantation. Am J Surg.2000;180:328–334.
5.
United Network for Organ Sharing Web site. Available at: http://www.unos.org. Accessed April 23, 2002.
6.
McDiarmidSVMillisMJOlthoffKMSoSK. Indications for pediatric liver transplantation. Pediatr Transplant.1998;2:106–116.
7.
EsquivelCOIwatsukiSGordonR. Indications for pediatric liver transplantation. J Pediatr.1987;111:1039–1045.
8.
MalatackJJSchiadDJUrbachAH. Choosing a pediatric recipient for orthotopic liver transplantation. J Pediatr.1987;111:479–489.
9.
BusuttilRWSeuPMillisJM. Liver transplantation in children. Ann Surg.1991;213:48–57.
10.
OtteJBDe Ville De GoyetJRedingR. Sequential treatment of biliary atresia with Kasai portoenterostomy and liver transplantation: A review. Hepatology. July 1994;20(1 pt 2):41S–48S.
11.
GossJAShackletonCRSwensonK. Orthotopic liver transplantation for congenital biliary atresia. An 11-year, single-center experience. Ann Surg.1996;224:276–284.
WeinbergAGMizeCEWorthenHG. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr.1976;88:434–438.
15.
SokalEBustosRVan HoofFOtteJB. Liver transplantation for hereditary tyrosinemia—early transplantation following the patient's stabilization. Transplantation.1992;54:937–939.
16.
LidofskySDBassNMPragerMC. Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology. July 1992;16:1–7.
17.
LidofskySD. Liver transplantation for fulminant hepatic failure. Gastroenterol Clin North Am.1993;22:257–269.
18.
O'GradyJGAlexanderGJHayllarKMWilliamsR. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology.1989;97:439–445.
19.
Adrian-CasavillaFReyesJTzakisA. Liver transplantation for neonatal hepatitis as compared to the other two leading indications for liver transplantation in children. J Hepatol.1994;21:1035–1039.
20.
OkuyamaK. Primary liver cell carcinoma associated with biliary cirrhosis due to congenital bile duct atresia. J Pediatr.1965;67:89.
21.
ReyesJDCarrBDvorchikI. Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence. J Pediatr.2000;136:795–804.
22.
SteigerESrpF. Morbidity and mortality related to home parenteral nutrition in patients with gut failure. Am J Surg. January 1983;145:102–105.
23.
AlagilleDEstradaAHadchouelMGauthierMOdievreMDommerguesJP. Syndromic paucity of interlobular bile duct (Alagille syndrome or arteriohepatic dysplagia): Review of 80 cases. J Pediatr.1987;110:195–200.
TarbellSEKosmachB. Parental psychosocial outcomes in pediatric liver and/or intestinal transplantation: Pretransplantation and the early postoperative period. Liver Transpl Surg.1998;4:378–387.
KalayogluMSollingerHWStrattaRJ. Extended preservation of the liver for clinical transplantation. Lancet.1988;1:617–619.
28.
TodoSNeryJYanagaK. Extended preservation of the human liver grafts with UW solution. JAMA.1989;261:711–714.
29.
GlanemannJMLangrehrARMullerAR. Incidence and risk factors of prolonged mechanical ventilation and causes of reintubation after liver transplantation. Transplant Proc.1998;30:1874–1875.
30.
GanschowRNolkemperDHelmkeK. Intensive care management after pediatric liver transplantation: A single-center experience. Pediatr Transplant.2000;4:273–279.
ShawBWWoodRPKauffmanSS. Liver transplantation therapy in children: Part II. J Pediatr Gastroenterol Nutr.1988;7:797–815.
33.
JordanSCRosenthalPMakowkaL. Immunosuppression in organ transplantation. Semin Pediatr Surg.1993;2:206–217.
34.
SchulakJAMayesJTMoritzCEHricikDE. A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients. Transplantation.1990;49:327–332.
35.
ReyesJJainAMazariegosG. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. Transplantation.2000;69:2573–2580.
36.
JainAMazariegosGKashyapR. Comparitive long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. Transplantation.2000;70:617–625.
37.
JainAMazariegosGKashyapR. Reasons why some children receiving tacrolimus therapy require steroids more than 5 years post liver transplantation. Pediatr Transplant. April 2001;5:93–98.
IwatsukiSStarzlTETodoS. Experience in 1000 liver transplants under cyclosporine-steroid therapy: A survival report. Transplant Proc.1988;20:498–504.
40.
KahanBD. Cyclosporine. N Engl J Med.1989;32:1725–1738.
41.
JainAReyesJKashyapR. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg.1999;230:441–449.
42.
AndrewsWSommerauerJRodenJ. 10 years of pediatric liver transplantation. J Pediatr Surg.1996;31:619–624.
43.
WatsonCJEFriendPJNevilleVJ. Sirolimus: A potent new immunosuppressant for liver transplantation. Transplantation.1999;67:505–509.
McAlisterVCPeltekianKMMalatjalianDA. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl.2001;7:701–708.
46.
SindhiRWebberSVenkataramananR. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation.2001;72:851–855.
47.
SollingerHW, for the US Renal Transplant Mycophenolate mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation.1995;60:225–232.
48.
The Tricontinental Mycophenolate Mofetil Transplantation Study Group.A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation.1996;61:1029–1037.
49.
GaberAOFirstMRTesiRJ. Results of the doubleblind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation.1998;66(1):29–37.
50.
DaoudAJSchroederTJKanoJHornHRMoranHBFirstMR. The US compassionate experience with thymoglobulin for the treatment of resistant acute rejection. Transplant Proc.1997;29(7A):18S–20S.
51.
TchervenkovJFlemmingCGuttmannRDDes GachonsG. Use of Thymoglobulin induction therapy in the prevention of acute graft rejection episodes following liver transplantation. Transplant Proc.1997;29(7A):13S–15S.
52.
CockfieldSMPreiksaitisJHarveyE. Is sequential use of ALG and OKT 3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder?Transplant Proc.1991;23:1106–1107.
53.
ChatenoudLBachJF. OKT3 in allogeneic transplantation: Clinical efficacy, mode of action and side effects. In: BurlinghamW, ed. A Critical Analysis of Monoclonal Antibody Therapy in Transplantation.Boca Raton, Fla: CRC; 1992.
54.
EckhoffDEMcGuireBSellersM. The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipient. Transplantation.2000;69:1867–1872.
55.
WisemanLRFauldsD. Daclizumab: A review of its use in the prevention of acute rejection in renal transplant recipients. Drugs.1999;58:1029–1042.
56.
NashanBMooreRAmlotP. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet.1997;350:1193–1198.
57.
KahanBRajagopalanPRHallM. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation.1999;67:276–284.
58.
McDiarmidSV. Risk factors and outcomes after pediatric liver transplantation. Liver Transpl Surg.1996;2(5suppl 1):44–56.
59.
ReyesJ. Critical complications of liver transplantation. In: CarlsonRReinesHD, eds. Critical Care: State of the Art.Aneheim, Calif: Society of Critical Care Medicine; 1992:353–387.
60.
MazariegosGVMolmentiEPKramerDJ. Early complications after orthotopic liver transplantation. Surg Clin North Am. February 1999;79:109–129.
61.
RagniMVLewisJHSperoJA. Bleeding and coagulation abnormalities in alcoholoic cirrhotic liver disease. Clin Exp Res.1982;6:267–274.
62.
RobertsonAJRelaMKaraniJHeatonND. Splenic artery aneurysm and orthotopic liver transplantation. Transpl Int.1999;12:68–70.
63.
DeRooverASudanD. Treatment of multiple aneurysms of the splenic artery after liver transplantation by percutaneous embolization and laparoscopic splenectomy. Transplantation.2001;72:956–958.
64.
Van der WerfWJD'AlessandroAMKnechtleSJ. Infant pediatric liver transplantation results equal those for older pediatric patients. J Pediatr Surg. January 1998;33:20–23.
65.
GossJAShackletonCRMcDiarmidSV. Long-term results of pediatric liver transplantation: An analysis of 569 transplants. Ann Surg.1998;228:411–420.
66.
YamanakaJLynchSVOngTH. Surgical complications and long-term outcome in pediatric liver transplantation. Hepatogastroenterology.2000;47:1371–1374.
67.
GrothCG. Changes in coagulation. In: StarzlTE, ed. Experiences in Hepatic Transplantation.Philadelphia, Pa: WB Saunders; 1969:159–175.
68.
TisoneGGunsonBKBuckelsJACMcMasterP. Raised hematocrit—a contributing factor to hepatic artery thrombosis following liver transplantation. Transplantation. July 1988;46:162–163.
69.
HarperPLLuddingtonRJCarrellRW. Protein C deficiency and portal thrombosis in liver transplantation in children. Lancet.1988;2:924–927.
70.
KokTHaagsmaEBKlompmakerIJ. Doppler ultrasound of the hepatic artery and vein performed daily in the first two weeks after orthotopic liver transplantation. Useful for the diagnosis of acute rejection?Invest Radiol. March 1996;31:173–179.
71.
McKeownCMBEdwardsVPhillipsMJ. Sinusoidal living cell damage: The critical injury in cold preservation of liver allograft in the rat. Transplantation.1988;46:178–191.
72.
YanagaKMakowkaLStarzlTE. Is hepatic artery thrombosis after liver transplantation really a surgical complication?Transplant Proc.1989;21:3511–3513.
73.
StahlRLDuncanAHooksMA. A hypercoagulable state follows orthotopic liver transplantation. Hepatology.1990;12(3 pt 1):553–558.
74.
MazzaferroVEsquivelCOMakowkaL. Hepatic artery thrombosis after pediatric liver transplantation—a medical or surgical event?Transplantation.1989;47:971–977.
75.
BadgerIBuckeelsJA. Hepatic artery thrombosis due to acute pancreatitis following liver transplantation. Transplantation.1989;48:526–527.
76.
DoddGDMemelGSZajkoAB. Hepatic artery stenosis and thrombosis in transplant recipients: Doppler diagnosis with resistive index and systolic acceleration time. Radiology.1994;192:657–661.
77.
BowenAHungateRGKayeRD. Imaging in liver transplantation. Radiol Clin North Am.1996;34:757–778.
78.
MazariegosGVO'TooleKMielesL. Hyperbaric oxygen therapy for hepatic artery thrombosis after liver transplantation in children. Liver Transpl Surg.1999;5:429–778.
79.
BusuttilRWSeuPMillisJM. Liver transplantation in children. Ann Surg. January 1991;213:48–57.
80.
LerutJTzakisAGBronK. Complications of venous reconstruction in human orthotopic liver transplantation. Ann Surg.1987;205:404–414.
81.
MarinoIREsquivelCOZajkoAB. Distal splenorenal shunt for portal vein thrombosis after liver transplantation. Am J Gastroenterol. January 1989;84:67–70.
82.
RouchDAEmondJCFerrariM. The successful management of portal vein thrombosis after hepatic transplantation with the splenorenal shunt. Surg Gynecol Obstet.1988;166:311–316.
83.
OstroffJWRobertsJPRingEF. The management of T-tube leaks in orthotopic liver transplant recipients with endoscopically placed nasobiliary catheters. Transplantation.1990;49:922–924.
84.
BhatriagarVDhawanAChaerH. The incidence and management of biliary complications following liver transplantation in children. Transpl Int.1995;8:388–391.
85.
Sanchez-UrdazpalLGoresGJWardEM. Diagnostic features and clinical outcome of ischemic-type biliary complications after liver transplantation. Hepatology.1993;17:605–609.
86.
McDiarmidSVBusuttilRWAscherNL. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. multicenter trial. Transplantation.1995;59:530–536.
87.
WiesnerRH. Is hepatic histology the true gold standard in diagnosing acute hepatic allograft rejection? [editorial]Liver Transpl Surg.1996;2:165–167.
88.
FisherLRHepleyKSLuceyMR. Acute cellular rejection after liver transplantation: Variability, morbidity, and mortality. Liver Transpl Surg.1995;1:10–15.
89.
LewisWDJenkinsRLBurkePA. FK506 rescue therapy in liver transplant recipients with drug-resistant rejection. Transplant Proc.1991;23:2989–2991.
90.
D'AllesandroAMKalayogluMPirschJD. FK506 rescue therapy for resistant rejection episodes in liver transplant recipients. Transplant Proc.1991;23:2987–2988.
91.
WinklerMRingeBGerstenkornC. Use of FK506 for treatment of chronic rejection after liver transplantation. Transplant Proc.1991;23;2984–2986.
92.
McDiarmidSVKlintmalmGBGBusuttilRW. FK506 conversion for intractable rejection of the liver allograft. Transpl Int.1993;6:305–312.
93.
McDiarmidSVWallacePVargasJAmentMEBusuttilRW. The treatment of intractable rejection with FK506 in pediatric liver transplant recipients. J Pediatr Gastroenterol Nutr.1994;20:291–294.
94.
ChardotCNicoluzziJEJanssenM. Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation. Transplantation.2001;71:224–229.
95.
GreenMMichaelsM. Infections in solid organ transplant recipients. In: LongSSProberCGPickeringLK, eds. Principles of Pediatric Infectitious Diseases.New York, NY: Churchill Livingstone; 1997:626–633.
96.
GarciaSRoqueJRuzaF. Infection and associated risk factors in the immediate postoperative period of pediatric liver transplantation: A study of 176 transplants. Clin Transplant. June 1998;12:190–197.
97.
BouchutJCStammDBoillotOLepapeAFloretD. Postoperative infectious complications in paediatric liver transplantation: A study of 48 transplants. Paediatr Anaesth. January 2001;11:93–98.
98.
RollinsNKAndrewsWSCurrinoG. Infected bile lakes following pediatric liver transplantation: Nonsurgical management. Radiology.1988;166:169–171.
99.
ZitelliBJGartnerJCMalatachJJ. Pediatric liver transplantation: Patient evaluation and selection, infectious complications, and life-style after transplantation. Transplant Proc.1987;19:3309–3316.
100.
ColonnaJOWinstonDJBrillJE. Infectious complications in liver transplantation. Arch Surg.1988;123:360–364.
101.
HiattJRAmentMEBerquistME. Pediatric liver transplantation at UCLA. Transplant Proc.1987;19:3282–3288.
102.
AndrewsWFyockBGrayS. Pediatric liver transplantation: The Dallas experience. Transplant Proc.1987;19:3267–3276.
103.
GreenMMichaelsM. Infectious complications of solid-organ transplantation in children. Adv Pediatr Infect Dis.1992;2:181–204.
104.
GladdyRARichardsonSEDaviesHDSuperinaRA. Candida infection in pediatric liver transplant recipients. Liver Transpl Surg. January 1999;5:16–24.
105.
Torre-CisnerosJManezRKusneS. Aspergillosis in liver transplantation. Transplant Proc.1991;23:3040–3041.
106.
SinghNDummerJSKusneS. Infections with cytomegalovirus and 121 liver transplant recipients: Transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis. July 1988;158:124–131.
107.
SatouJFunatoTSatohN. Quantitative PCR determination of human cytomegalovirus in blood cells. J Clin Lab Anal.2001;15(3):122–126.
108.
DussaixEWoodC. Cytomegalovirus infection in pediatric liver recipients: A virological survey and prophylaxis with CMV immune globulin and early DHPG treatment. Transplantation.1989;48:272–274.
109.
PehlivanogluEAmentMESpolidoroJVVarasJBusuttilRBerquistWE. Severe cytomegalovirus infection and immunosuppressive therapy in pediatric liver transplantation. Turk J Pediatr. January-March 1990;32:3–11.
110.
LautenschlagerIHockerstedtKSalmelaK. Good and impaired response to ganciclovir treatment of severe CMV infections in liver transplant recipients. Transplant Int.1994;7(suppl 1):S232–S234.
111.
SanoKTanakaKUemotoS. Cytomegalovirus infection in living related liver transplantation: Rapid diagnosis by human monoclonal antibody staining of blood leucocytes. Transplant Sci. September 1994;4:105–111.
112.
StrattaRJShaeferMSMarkinRS. Clinical patterns of cytomegalovirus disease after liver transplantation. Arch Surg.1989;124:1443–1450.
113.
GreenMKaufmannMWilsonJReyesJ. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis.1997;25:1344–1349.
114.
BreiningMKZitelliBStarzlTE. Epstein-Barr virus, cytomegalovirus and other virus infections in children after transplantation. J Infect Dis.1987;156:273–279.
115.
CoxKLLawrence-MiyasakiLSGarcia-KennedyR. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disease in young children on FK506 after liver transplantation. Transplantation.1995;59:524–529.
116.
NewellKAAlonsoEMWhitingtonPF. Posttransplant lymphoproliferative disease in pediatric liver transplantation: Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation.1996;6:370–375.
117.
SokalEMAntunesHBeguinC. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation.1997;64:1438–1442.
118.
YounesBSMcDiarmidSVMartinMG. The effects of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation.2000;70:94–99.
119.
YounesBSAmentMEMcDiarmidSVMartinMGVargasJH. The involvement of the gastrointestinal tract in posttransplant lymphoproliferative disease in pediatric liver transplantation. J Pediatr Gastroenterol Nutr.1999;28:375–376.
120.
CaoSCoxKEsquivelCO. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation. Transplantation.1998;66:851–856.
121.
GreenMCacciarelliTVMazariegosGV. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for post-transplant lymphoproliferative disease. Transplantation.1998;66:1641–1644.
122.
McDiarmidSVJordanSKimGS. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation.1998;66:1604–1611.
123.
CacciarelliTVGreenMJaffeR. Management of post-transplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation.1998;66:1047–1052.
124.
GreenMWaldERFrickerFSGriffithBPTrentoA. Infections in pediatric orthotopic heart transplant recipients. Pediatr Infect Dis J. February 1989;8:87–93.
125.
TrachmanHWeissRASpiglandI. Clinical manifestations of herpesvirus infections in pediatric renal transplant recipients. Pediatr Infect Dis J.1985;4:480–486.
126.
BunchmanTENevinsTEMauerSM. Viral complications of OKT3 monoclonal antibody in children undergoing renal transplantation. Transplant Proc.1989;21:1761–1762.
127.
WongDL, ed. Whaley and Wong's Nursing Care of Infants and Children.St Louis, Mo: Mosby; 1995.
128.
AndersonLJ. Role of parvovirus B19 in human disease. Pediatr Infect Dis J.1987;6:711–718.
129.
GallinellaGManaresiEVenturoliS. Occurrence and clinical role of active parvovirus B19 infection in transplant recipients. Eur J Clin Microbiol Infect Dis.1999;18:811–813.
VesseySJChanCYKuterBJ. Childhood vaccination against varicella: Persistence of antibody, duration of protection, and vaccine efficacy. J Pediatr.2001;139:297–304.
132.
DonatiMZuckermanMDhawanA. Response to varicella immunization in pediatric liver transplant recipients. Transplantation.2000;70:1401–1404.
133.
GiacchinoRMarcelliniMTimitilliA. Varicella vaccine in children requiring renal or hepatic transplantation. Transplantation.1995;60:1055–1056.
134.
PandyaAWasfySHevertDAllenUD. Varicella-zoster infection in pediatric solid-organ transplant recipients: A hospital-based study in the prevaricella vaccine era. Pediatr Transplant. June 2001;5:153–159.
